Clinical trial · Observational
Immunomodulation Analysis of Radiation Therapy in Pediatric Malignant Brain Tumors
Immunomodulation Analysis on Peripheral Blood Mononuclear Cells of Radiation Therapy in Pediatric Malignant Brain Tumors
NCT04019470CI-TRIAL-00073788withdrawnClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Why stopped (as posted): No participants enrolled
Summary
Brief summary (as posted)
To investigate the effect of radiotherapy on peripheral blood immune cell composition and function in pediatric malignant brain tumor patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Brain Tumor, Pediatric | Childhood Brain Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- The changes of peripheral blood immune cells
- timeFrame
- 6 weeks (prior and post the radiation therapy )
- description
- The flow cytometric analysis of lymphocyte subtypes populations would be performed
Secondary outcomes (2)
- measure
- Activation status of T cells
- timeFrame
- 6 weeks (prior and post the radiation therapy )
- description
- Activation status of peripheral IFN-γ-producing effector CD8+ T cells by Elispot.
- measure
- The changs of inflammatory cytokines and chemokines
- timeFrame
- 6 weeks (prior and post the radiation therapy )
- description
- Human inflammatory cytokines and chemokines will be analyzed by ELISA during radiation therapy. The cytokines and chemokines are IL-2, IL-10, IFN-γ, TNF-α
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 3 Years
- Maximum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Age from 3 to 18 * To be diagnosed with malignant brain tumors * To eligible for radiation therapy * Karnofsky performance status ≥ 70 * No prior radiation exposure * Informed consent signed for blood sample collection and used for research purpose Exclusion Criteria: * Patients had received radiotherapy previously. * Patients who had no histological diagnosis * Patients who do not wish to participate * Patients with infections
References
Publications (0)
Data not yet available
No reference posted for this study.